Biomerica, Inc. announced that it and its CLIA laboratory partner have submitted an application to the American Medical Association (AMA) CPT Editorial Panel requesting the assignment of a Proprietary Laboratory Analysis (PLA) code for the inFoods IBS diagnostic test. This application represents a key strategic milestone towards broadening patient access to the inFoods IBS product. If granted, the PLA code will provide a test-specific code for submitting claims to Medicare and other insurers.
The establishment of a PLA code for inFoods IBS will allow for transparency in claims submission and adjudication, which is essential for accelerating physician adoption and expanding patient access. CEO Zack Irani emphasized that insurance reimbursement is critical to unlocking the full commercial value of the inFoods technology platform. The inFoods IBS test is a novel, non-invasive diagnostic that identifies patient-specific IBS trigger foods, offering a differentiated approach to managing symptoms.
IBS affects an estimated 10% to 15% of adults in the U.S. and contributes to billions of dollars in healthcare costs annually, representing a significant unmet need. Clinical trial results published in *Gastroenterology* demonstrated that patients following an inFoods-guided diet experienced significantly greater symptom relief. This application positions inFoods IBS as a category-defining diagnostic, with the potential to transform how IBS and other GI-related disorders are diagnosed and managed.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.